New approaches to management of neonatal hypoglycemia

Paul J Rozance, William W Hay Jr, Paul J Rozance, William W Hay Jr

Abstract

Despite being a very common problem after birth, consensus on how to manage low glucose concentrations in the first 48 h of life has been difficult to establish and remains a debated issue. One of the reasons for this is that few studies have provided the type of data needed to establish a definitive approach agreed upon by all. However, some recent publications have provided much needed primary data to inform this debate. These publications have focused on aspects of managing low blood glucose concentrations in the patients most at-risk for asymptomatic hypoglycemia-those born late-preterm, large for gestational age, small for gestational age, or growth restricted, and those born following a pregnancy complicated by diabetes mellitus. The goal of this review is to discuss specific aspects of this new research. First, we focus on promising new data testing the role of buccal dextrose gel in the management of asymptomatic neonatal hypoglycemia. Second, we highlight some of the clinical implications of a large, prospective study documenting the association of specific glycemic patterns with neurodevelopmental outcomes at two years of age.

Keywords: Continuous glucose monitoring; Dextrose gel; Infant of a diabetic mother; Intrauterine growth restriction; Large for gestational age; Late preterm; Neonatal hypoglycemia; Small for gestational age.

References

    1. Boardman JP, Wusthoff CJ, Cowan FM. Hypoglycaemia and neonatal brain injury. Arch Dis Child Educ Pract Ed. 2013;98:2–6. doi: 10.1136/archdischild-2012-302569.
    1. Hawdon JM. Definition of neonatal hypoglycaemia: time for a rethink? Arch Dis Child Fetal Neonatal Ed. 2013;98:F382–F383. doi: 10.1136/archdischild-2012-303422.
    1. Rozance PJ, Hay WW. Hypoglycemia in newborn infants: features associated with adverse outcomes. Biol Neonate. 2006;90:74–86. doi: 10.1159/000091948.
    1. Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127:575–579. doi: 10.1542/peds.2010-3851.
    1. Adamkin DH. Neonatal hypoglycemia. Curr Opin Pediatr. 2016;28:150–5. doi: 10.1097/MOP.0000000000000319.
    1. Adamkin DH, Polin R. Neonatal hypoglycemia: is 60 the new 40? The questions remain the same. J Perinatol. 2016;36:10–12. doi: 10.1038/jp.2015.125.
    1. Stanley CA, Rozance PJ, Thornton PS, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI. Re-evaluating “transitional neonatal hypoglycemia”: mechanism and implications for management. J Pediatr. 2015;166:1520–1525. doi: 10.1016/j.jpeds.2015.02.045.
    1. Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Rozance PJ, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167:238–245. doi: 10.1016/j.jpeds.2015.03.057.
    1. Hay WW, Jr, Raju TN, Higgins RD, Kalhan SC, Devaskar SU. Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr. 2009;155:612–617. doi: 10.1016/j.jpeds.2009.06.044.
    1. Arcangeli T, Thilaganathan B, Hooper R, Khan KS, Bhide A. Neurodevelopmental delay in small babies at term: a systematic review. Ultrasound Obstet Gynecol. 2012;40:267–275. doi: 10.1002/uog.11112.
    1. Brand PL, Molenaar NL, Kaaijk C, Wierenga WS. Neurodevelopmental outcome of hypoglycaemia in healthy, large for gestational age, term newborns. Arch Dis Child. 2005;90:78–81. doi: 10.1136/adc.2003.039412.
    1. Stenninger E, Flink R, Eriksson B, Sahlen C. Long-term neurological dysfunction and neonatal hypoglycaemia after diabetic pregnancy. Arch Dis Child Fetal Neonatal Ed. 1998;79:F174–F179. doi: 10.1136/fn.79.3.F174.
    1. von Beckerath AK, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P. Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. Am J Obstet Gynecol. 2013;208:130–136.
    1. American Academy of Pediatrics Committee on Fetus and Newborn Routine evaluation of blood pressure, hematocrit, and glucose in newborns. Pediatrics. 1993;92:474–476.
    1. Barry JS, Rozance PJ, Brown LD, Anthony RV, Thornburg KL, Hay WW Jr. Increased fetal myocardial sensitivity to insulin-stimulated glucose metabolism during ovine fetal growth restriction. Exp Biol Med (Maywood). 2016. [Epub ahead of print].
    1. Leos RA, Anderson MJ, Chen X, Pugmire J, Anderson KA, Limesand SW. Chronic exposure to elevated norepinephrine suppresses insulin secretion in fetal sheep with placental insufficiency and intrauterine growth restriction. Am J Physiol Endocrinol Metab. 2010;298:E770–E778. doi: 10.1152/ajpendo.00494.2009.
    1. Limesand SW, Rozance PJ, Zerbe GO, Hutton JC, Hay WW., Jr Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. Endocrinology. 2006;147:1488–1497. doi: 10.1210/en.2005-0900.
    1. Limesand SW, Rozance PJ, Smith D, Hay WW., Jr Increased insulin sensitivity and maintenance of glucose utilization rates in fetal sheep with placental insufficiency and intrauterine growth restriction. Am J Physiol Endocrinol Metab. 2007;293:E1716–E1725. doi: 10.1152/ajpendo.00459.2007.
    1. Macko AR, Yates DT, Chen X, Green AS, Kelly AC, Brown LD, Limesand SW. Elevated plasma norepinephrine inhibits insulin secretion, but adrenergic blockade reveals enhanced beta-cell responsiveness in an ovine model of placental insufficiency at 0.7 of gestation. J Dev Orig Health Dis. 2013;4:402–10. doi: 10.1017/S2040174413000093.
    1. Thorn SR, Brown LD, Rozance PJ, Hay WW, Jr, Friedman JE. Increased hepatic glucose production in fetal sheep with intrauterine growth restriction is not suppressed by insulin. Diabetes. 2013;62:65–73. doi: 10.2337/db11-1727.
    1. Brown LD, Rozance PJ, Thorn SR, Friedman JE, Hay WW., Jr Acute supplementation of amino acids increases net protein accretion in IUGR fetal sheep. Am J Physiol Endocrinol Metab. 2012;303:E352–E364. doi: 10.1152/ajpendo.00059.2012.
    1. Brown LD. Endocrine regulation of fetal skeletal muscle growth: impact on future metabolic health. J Endocrinol. 2014;221:R13–R29. doi: 10.1530/JOE-13-0567.
    1. Brown LD, Rozance PJ, Bruce JL, Friedman JE, Hay WW, Jr, Wesolowski SR. Limited capacity for glucose oxidation in fetal sheep with intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol. 2015;309:R920–R928. doi: 10.1152/ajpregu.00197.2015.
    1. Limesand SW, Jensen J, Hutton JC, Hay WW., Jr Diminished beta-cell replication contributes to reduced beta-cell mass in fetal sheep with intrauterine growth restriction. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1297–R1305. doi: 10.1152/ajpregu.00494.2004.
    1. Limesand SW, Rozance PJ, Macko AR, Anderson MJ, Kelly AC, Hay WW., Jr Reductions in insulin concentrations and beta-cell mass precede growth restriction in sheep fetuses with placental insufficiency. Am J Physiol Endocrinol Metab. 2013;304:E516–E523. doi: 10.1152/ajpendo.00435.2012.
    1. Rozance PJ, Hay WW Jr. Pancreatic islet hepatocyte growth factor and vascular endothelial growth factor A signaling in growth restricted fetuses. Mol Cell Endocrinol. 2016. [Epub ahead of print].
    1. Thorn SR, Regnault TRH, Brown LD, Rozance PJ, Keng J, Roper M, Wilkening RB, Hay WW, Jr, Friedman JE. Intrauterine growth restriction increases fetal hepatic gluconeogenic capacity and reduces messenger ribonucleic acid translation initiation and nutrient sensing in fetal liver and skeletal muscle. Endocrinology. 2009;150:3021–3030. doi: 10.1210/en.2008-1789.
    1. Wesolowski SR, Hay WW Jr. Role of placental insufficiency and intrauterine growth restriction on the activation of fetal hepatic glucose production. Mol Cell Endocrinol. 2015. [Epub ahead of print].
    1. Yates DT, Green AS, Limesand SW. Catecholamines mediate multiple fetal adaptations during placental insufficiency that contribute to intrauterine growth restriction: lessons from hyperthermic sheep. J Pregnancy. 2011;2011:740408. doi: 10.1155/2011/740408.
    1. Yates DT, Clarke DS, Macko AR, Anderson MJ, Shelton LA, Nearing M, Allen RE, Rhoads RP, Limesand SW. Myoblasts from intrauterine growth-restricted sheep fetuses exhibit intrinsic deficiencies in proliferation that contribute to smaller semitendinosus myofibres. J Physiol. 2014;592:3113–3125. doi: 10.1113/jphysiol.2014.272591.
    1. Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. Ann Surg. 1935;101:1299–1335. doi: 10.1097/00000658-193506000-00001.
    1. Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:2077–2083. doi: 10.1016/S0140-6736(13)61645-1.
    1. Alexandrou G, Skiold B, Karlen J, Tessma MK, Norman M, Aden U, Vanpee M. Early hyperglycemia is a risk factor for death and white matter reduction in preterm infants. Pediatrics. 2010;125:e584–e591. doi: 10.1542/peds.2009-0449.
    1. McKinlay CJ, Alsweiler JM, Ansell JM, Anstice NS, Chase JG, Gamble GD, Harris DL, Jacobs RJ, Jiang Y, Paudel N, Signal M, Thompson B, Wouldes TA, Yu TY, Harding JE. Neonatal glycemia and neurodevelopmental outcomes at 2 years. N Engl J Med. 2015;373:1507–1518. doi: 10.1056/NEJMoa1504909.
    1. Lilien LD, Pildes RS, Srinivasan G, Voora S, Yeh TF. Treatment of neonatal hypoglycemia with minibolus and intraveous glucose infusion. J Pediatr. 1980;97:295–298. doi: 10.1016/S0022-3476(80)80499-9.
    1. Harris DL, Alsweiler JM, Ansell JM, Gamble GD, Thompson B, Wouldes TA, Yu TY, Harding JE. Outcome at 2 years after dextrose gel treatment for neonatal hypoglycemia: follow-up of a randomized trial. J Pediatr. 2016;170:54–59. doi: 10.1016/j.jpeds.2015.10.066.
    1. Srinivasan G, Pildes RS, Cattamanchi G, Voora S, Lilien LD. Plasma glucose values in normal neonates: a new look. J Pediatr. 1986;109:114–117. doi: 10.1016/S0022-3476(86)80588-1.
    1. Woo HC, Tolosa L, El-Metwally D, Viscardi RM. Glucose monitoring in neonates: need for accurate and non-invasive methods. Arch Dis Child Fetal Neonatal Ed. 2014;99:F153–F157. doi: 10.1136/archdischild-2013-304682.
    1. Bennett C, Fagan E, Chaharbakhshi E, Zamfirova I, Flicker J. Implementing a protocol using glucose Gel to treat neonatal hypoglycemia. Nurs Womens Health. 2016;20:64–74. doi: 10.1016/j.nwh.2015.11.001.
    1. Stewart CE, Sage EL, Reynolds P. Supporting ‘Baby Friendly’: a quality improvement initiative for the management of transitional neonatal hypoglycaemia. Arch Dis Child Fetal Neonatal Ed. 2015. [Epub ahead of print].
    1. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, van Weissenbruch M, Midgley P, Thompson M, Thio M, Cornette L, Ossuetta I, Iglesias I, Theyskens C, de Jong M, Ahluwalia JS, de Zegher F, Dunger DB. Early insulin therapy in very-low-birth-weight infants. N Engl J Med. 2008;359:1873–1884. doi: 10.1056/NEJMoa0803725.
    1. Harris DL, Battin MR, Weston PJ, Harding JE. Continuous glucose monitoring in newborn babies at risk of hypoglycemia. J Pediatr. 2010;157:198–202. doi: 10.1016/j.jpeds.2010.02.003.
    1. Hay WW, Jr, Rozance PJ. Continuous glucose monitoring for diagnosis and treatment of neonatal hypoglycemia. J Pediatr. 2010;157:180–182. doi: 10.1016/j.jpeds.2010.04.007.
    1. Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. J Pediatr. 2012;161:787–791. doi: 10.1016/j.jpeds.2012.05.022.
    1. Rozance PJ, Hay WW., Jr Neonatal hypoglycemia--answers, but more questions. J Pediatr. 2012;161:775–776. doi: 10.1016/j.jpeds.2012.06.034.
    1. Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study. Pediatrics. 2006;117:2231–2243. doi: 10.1542/peds.2005-1919.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit